1. Home
  2. MLYS vs CHCO Comparison

MLYS vs CHCO Comparison

Compare MLYS & CHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$20.29

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo City Holding Company

CHCO

City Holding Company

SELL

Current Price

$141.48

Market Cap

2.1B

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
MLYS
CHCO
Founded
2019
1957
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.1B
IPO Year
2023
1995

Fundamental Metrics

Financial Performance
Metric
MLYS
CHCO
Price
$20.29
$141.48
Analyst Decision
Strong Buy
Hold
Analyst Count
11
5
Target Price
$46.33
★ $142.40
AVG Volume (30 Days)
★ 1.4M
103.6K
Earning Date
11-09-2026
10-26-2026
Dividend Yield
N/A
★ 2.84%
EPS Growth
★ 37.43
13.18
EPS
N/A
★ 4.55
Revenue
N/A
N/A
Revenue This Year
N/A
$4.24
Revenue Next Year
N/A
$3.28
P/E Ratio
★ N/A
$30.95
Revenue Growth
N/A
N/A
52 Week Low
$20.41
$113.21
52 Week High
$47.65
$148.99

Technical Indicators

Market Signals
Indicator
MLYS
CHCO
Relative Strength Index (RSI) 32.24 50.34
Support Level N/A $137.70
Resistance Level $31.19 $145.96
Average True Range (ATR) 1.27 2.25
MACD -0.29 0.10
Stochastic Oscillator 4.06 59.93

Price Performance

Historical Comparison
MLYS
CHCO

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

About CHCO City Holding Company

City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.

Share on Social Networks: